Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.
about
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesHPV related diseases in males: a heavy vaccine-preventable burdenMale circumcision and human papillomavirus infection in men: a systematic review and meta-analysisIncidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men.Analysis of longitudinal multivariate outcome data from couples cohort studies: application to HPV transmission dynamics.Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance.Human papillomavirus knowledge and vaccine acceptability among a national sample of heterosexual menHigh-risk human papillomavirus viral load and persistence among heterosexual HIV-negative and HIV-positive menA modeling framework for the analysis of HPV incidence and persistence: a semi-parametric approach for clustered binary longitudinal data analysisThe potential impact of HPV-16 reactivation on prevalence in older Australians.Risky sexual behavior in adolescent survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.Human papillomavirus-related disease in men: not just a women's issueHPV vaccine for adolescent males: acceptability to parents post-vaccine licensure.Meta-analysis of human papillomavirus infection concordance.Human papillomavirus infection in a male population attending a sexually transmitted infection service.The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental modelsEpidemiology and pathology of HPV disease in males.HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland.HPV vaccine acceptability in heterosexual, gay, and bisexual men.External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continentsFactors affecting the prevalence of strongly and weakly carcinogenic and lower-risk human papillomaviruses in anal specimens in a cohort of men who have sex with men (MSM).Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adultsIncidence and clearance of genital human papillomavirus infection in men (HIM): a cohort studyHuman papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study)Evolutionary ecology of human papillomavirus: trade-offs, coexistence, and origins of high-risk and low-risk typesThe incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature.Human papillomavirus incidence and clearance among HIV-positive and HIV-negative men in sub-Saharan Africa.Human Papillomavirus Vaccine Initiation among 9-13-Year-Olds in the United States.Genital HPV infection and related lesions in menHealth service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.Sexual behaviour and less frequent bathing are associated with higher human papillomavirus incidence in a cohort study of uncircumcised Kenyan men.New Approaches to Immunotherapy for HPV Associated Cancers.The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.Role and uptake of human papillomavirus vaccine in adolescent health in the United StatesAn update on oral human papillomavirus infection.Vulvar condylomatosis after sex reassignment surgery in a male-to-female transsexual: Complete response to imiquimod creamA prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know.Variation in genital human papillomavirus infection prevalence and vaccination coverage among men and women in the USA.
P2860
Q24614644-7B86FB68-61AE-432C-BED1-84FDF61E4CCFQ27010120-045ACE4B-FC6E-4A3B-97A0-661108F96B5AQ28249522-2D8F173E-B010-4186-8817-4614E6B4C7D0Q30457368-349EC45D-1927-4FED-9171-26546EF83840Q30981780-75E03425-AE5B-4653-965F-9C5EB624B5BCQ33574992-C1B191A0-7E8E-4641-9B63-19801DFDE3E7Q33638299-3C98AE20-9BEC-404D-9D5F-41064F84F2F0Q33647410-EF10C2C0-20FA-442D-837D-BE6BB76C0BE5Q33691903-78126C48-D529-426B-AF76-82B8A5520CFFQ33769284-0514E6C5-B05C-4CC0-8834-A1AE12059C51Q33794143-808717A6-7C41-4638-9FE9-E66E548BF28CQ33855416-35CAC26D-A273-440F-864A-0BCDA515FF4BQ34097592-9EF48DB2-A025-4E34-B936-6B7598A62F1AQ34293114-35A0347A-23F1-49A0-883C-4D48FB17EEE0Q34571148-7DE7B006-0735-4DC9-AC13-47CE82501D52Q34583160-4607A6DA-749B-42AD-9D87-EA41E74586DFQ34627327-A29E7197-7849-4E04-AEAF-E3EE5763056FQ34745786-C0D0572E-13ED-44C3-A3BD-B21B3F20CD98Q34872733-8B8F5398-0D8D-4F49-A471-3100896BA8BDQ34910428-AA3BE959-E347-4CFE-9DE1-093EA416F941Q35053172-C52D6C8F-161E-44BF-A6CA-342ACCD28753Q35195399-B039974E-9C2A-4F29-8FE1-5884FEB553A1Q35558548-24D2F90A-AE48-4CDC-8876-A51F8216944BQ35596225-E7458051-641D-4490-85F4-E6454B71C23FQ35596329-D3078857-09E6-4422-A237-273FD32FC45BQ35628646-B52BBA36-5814-4235-92DE-EF37B289E800Q36052323-ECF2BF5D-38C7-45EA-B45A-80EFE8E1051FQ36235594-F88B653F-B4EF-4E6D-835F-08A3DFD5435DQ36298355-D575A0FE-F709-416A-AC85-8ECF1FA09FB9Q36389950-654A3B66-F716-4D96-AD1C-6D49D88B3E4CQ36707477-F3FBF8C0-157A-4E1C-A24B-7A04DE1EE0E3Q36979772-4E8556E7-4434-4209-B902-3A6892F5CD4EQ37137430-73BF3C0B-A2DF-41D4-99C0-302B316744B2Q37232535-342F4418-14D9-4312-8AFB-3F4BABA19DE0Q37244355-FA22830A-6718-43B0-AE9C-3892D90EBD02Q37345680-406C40DA-8A8E-4E4B-932E-A29AA40C0C0AQ37711847-13D7D2B1-58AB-4557-81D8-54080A1A8564Q38006991-1E912EC8-38A9-4709-A517-5DD89A6F5726Q38023262-223A6638-D68B-4D48-A112-C6603C8C34E1Q38673856-B13E9F8F-98C0-45BB-97CC-8E8BE6C52DCB
P2860
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@ast
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@en
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@nl
type
label
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@ast
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@en
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@nl
prefLabel
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@ast
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@en
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@nl
P2093
P2860
P356
P1476
Age-specific prevalence, incid ...... ons in a cohort of 290 US men.
@en
P2093
Anna R Giuliano
Carrie M Nielson
Ji-Hyun Lee
Martha Abrahamsen
Mary R Papenfuss
Roberto Flores
Robin B Harris
P2860
P304
P356
10.1086/591095
P407
P577
2008-09-01T00:00:00Z